
Human Macrophage migration inhibitory factor 19-27, FLSELTQQL
Description
About Human Macrophage migration inhibitory factor 19-27, FLSELTQQL
The Human Macrophage migration inhibitory factor Peptide (IEDB: 156656) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Macrophage migration inhibitory factor Peptide, H-FLSELTQQL-OH (Uniprot: P14174 aa: 19-27) from JPT is produced under strict quality control and quality management.
Human Macrophage migration inhibitory factor 19-27, FLSELTQQL - Specifications
- Peptide sequence: H-FLSELTQQL-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Breast cancer, Leukemia
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Macrophage migration inhibitory factor 19-27, FLSELTQQL
References:
Read References with JPT’s Antigen Peptides
Human Macrophage migration inhibitory factor 19-27, FLSELTQQL has been described in:
Although divergent in residues of the peptide binding site, conserved chimpanzee Patr-AL and polymorphic human HLA-A*02 have overlapping peptide-binding repertoires., J Immunol, 2011 (PMID: 21209280)
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome., PLoS One, 2015 (PMID: 26375851)
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups., Vaccines (Basel), 2021 (PMID: 33923363)
Documentation
Documentation for Human Macrophage migration inhibitory factor 19-27, FLSELTQQL
Properties
Properties of Human Macrophage migration inhibitory factor 19-27, FLSELTQQL
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Breast cancer, Leukemia |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Macrophage migration inhibitory factor |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Macrophage migration inhibitory factor 19-27, FLSELTQQL
Information | Values |
---|---|
Sequence: | H-FLSELTQQL-OH |
Specifications: | 9mer peptide as TFA salt |